353 related articles for article (PubMed ID: 30902022)
1. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
Relke N; Gooderham M
J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
[TBL] [Abstract][Full Text] [Related]
2. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
Sardana K; Muddebihal A; Khurana A
Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
[TBL] [Abstract][Full Text] [Related]
4. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
Phan K; Phan S; Shumack S; Gupta M
J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
[TBL] [Abstract][Full Text] [Related]
5. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Liu LY; Strassner JP; Refat MA; Harris JE; King BA
J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
[TBL] [Abstract][Full Text] [Related]
6. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
7. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
8. Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo.
Pranić S; Pulumati A; Vuković D
Syst Rev; 2024 Apr; 13(1):110. PubMed ID: 38641831
[TBL] [Abstract][Full Text] [Related]
9. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
10. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Niu C; Xie H; Aisa HA
Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitors for the treatment of vitiligo.
Inoue S; Suzuki T; Sano S; Katayama I
J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Craiglow BG; King BA
JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
[TBL] [Abstract][Full Text] [Related]
13. A Bioinformatic Study on the Potential Anti-Vitiligo Activity of a
Trigui E; Ben Hassen H; Zaghden H; Trigui M; Achour S
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005266
[TBL] [Abstract][Full Text] [Related]
14. Biologic and targeted therapeutics in vitiligo.
Karagaiah P; Schwartz RA; Lotti T; Wollina U; Grabbe S; Goldust M
J Cosmet Dermatol; 2023 Jan; 22(1):64-73. PubMed ID: 35029034
[TBL] [Abstract][Full Text] [Related]
15. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo.
Iwanowski T; Kołkowski K; Nowicki RJ; Sokołowska-Wojdyło M
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298700
[TBL] [Abstract][Full Text] [Related]
16. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo.
Yousefian F; Yadlapati S; Browning JC
J Cosmet Dermatol; 2023 Mar; 22(3):1105-1107. PubMed ID: 36440703
[TBL] [Abstract][Full Text] [Related]
17. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
19. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
20. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
Grossmann MC; Haidari W; Feldman SR
J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]